# From microtubule remodeling to clinical translation: the multifaceted roles of vasohibin-1 in disease modulation

**Authors:** Keke Wei, Hui Li, Huiquan Huang, Yinyan Ban, Xiangbin Luo, Chaoren Zhang, Jian Guo, Minghua Tan, Minzhen Qin

PMC · DOI: 10.3389/fimmu.2026.1759658 · Frontiers in Immunology · 2026-02-09

## TL;DR

Vasohibin-1 (VASH-1) is a protein involved in blood vessel regulation and has complex roles in diseases, making it a potential target for diagnosis and treatment.

## Contribution

This review systematically explores VASH-1's multi-dimensional roles, paradoxical functions, and translational potential across diseases.

## Key findings

- VASH-1 regulates vascular homeostasis through microtubule remodeling.
- It shows paradoxical expression in different cancers, inhibiting or promoting angiogenesis.
- VASH-1 serves as a diagnostic marker and therapeutic target in renal and cancer diseases.

## Abstract

Vasohibin-1 (VASH-1) is an endothelial protein that serves as a negative feedback regulator of angiogenesis. Through its microtubule carboxypeptidase activity, VASH-1 plays a key role in vascular homeostasis. While previous studies have investigated its involvement in vascular regulation, most have focused on isolated functions or specific disease models, without systematically addressing its multi-dimensional regulatory mechanisms, tissue-specific functional paradoxes, and translational potential. This review provides a comprehensive analysis of VASH-1’s biological characteristics: its expression is induced by pro-angiogenic factors, and it forms a functional complex with SVBP. In pathological contexts, VASH-1 exhibits paradoxical expression patterns—downregulated in neuroendocrine tumors but upregulated in bladder cancer—and demonstrates tissue-specific functions that either inhibit or promote angiogenesis. Clinically, VASH-1 serves both as a diagnostic marker (e.g., serum biomarker and tissue-based prognostic indicator) and a therapeutic target (such as improving renal disease or promoting tumor vascular normalization). This review aims to elucidate the complex physiological and pathological roles of VASH-1, providing a foundation for future precision intervention strategies targeting VASH-1 in disease diagnosis and therapy.

Diagram illustrating the roles of VASH-1 in disease modulation. Center features VASH-1 structure. Top left: Microtubule remodeling with α-tubulin detyrosination. Top right: Angiogenesis regulation with endothelial cells and vascular homeostasis. Bottom left: Disease modulation showing cancer, renal diseases, and autoimmune disorders. Bottom right: Clinical translation highlighting biomarkers and therapeutic targets.

## Linked entities

- **Genes:** VASH1 (vasohibin 1) [NCBI Gene 22846], SVBP (small vasohibin binding protein) [NCBI Gene 374969], LOC126710533 (tubulin alpha chain-like) [NCBI Gene 126710533]
- **Proteins:** VASH1 (vasohibin 1), SVBP (small vasohibin binding protein), LOC126710533 (tubulin alpha chain-like)
- **Diseases:** bladder cancer (MONDO:0004986), renal disease (MONDO:0005240)

## Full-text entities

- **Genes:** Acsl4 (acyl-CoA synthetase long-chain family member 4) [NCBI Gene 50790] {aka 9430020A05Rik, ACS4, Facl4, Lacs4}, Pbd2 (peak bone density 2) [NCBI Gene 109445] {aka Cti1}, VASH1 (vasohibin 1) [NCBI Gene 22846] {aka KIAA1036, TTCP 1}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, ESM1 (endothelial cell specific molecule 1) [NCBI Gene 11082] {aka endocan}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, CD82 (CD82 molecule) [NCBI Gene 3732] {aka 4F9, C33, GR15, IA4, KAI1, R2}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, NT5C3A (5'-nucleotidase, cytosolic IIIA) [NCBI Gene 51251] {aka CNSHA8, NT5C3, P5'N-1, P5N-1, PN-I, POMP}, MACC1 (MET transcriptional regulator MACC1) [NCBI Gene 346389] {aka 7A5, SH3BP4L}, CD34 (CD34 molecule) [NCBI Gene 947], EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, VASH2 (vasohibin 2) [NCBI Gene 79805], Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 2146] {aka ENX-1, ENX1, EZH2b, KMT6, KMT6A, WVS}, Vash1 (vasohibin 1) [NCBI Gene 238328] {aka D930046M13Rik, G630009D10Rik, TTCP 1}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, PRKCD (protein kinase C delta) [NCBI Gene 5580] {aka ALPS3, CVID9, MAY1, PKCD, nPKC-delta}, MIR4530 (microRNA 4530) [NCBI Gene 100616163], MIR1269A (microRNA 1269a) [NCBI Gene 100302177] {aka MIR1269, MIRN1269, hsa-mir-1269, hsa-mir-1269a}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, FLG (filaggrin) [NCBI Gene 2312] {aka ATOD2, FLG-1, FLG1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, CCNB1 (cyclin B1) [NCBI Gene 891] {aka CCNB}, Gpx4 (glutathione peroxidase 4) [NCBI Gene 625249] {aka GPx-4, GSHPx-4, PHGPx, mtPHGPx, snGPx}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, PINK1 (PTEN induced kinase 1) [NCBI Gene 65018] {aka BRPK, PARK6}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}, EPB42 (erythrocyte membrane protein band 4.2) [NCBI Gene 2038] {aka PA, SPH5}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, SPINK1 (serine peptidase inhibitor Kazal type 1) [NCBI Gene 6690] {aka PCTT, PSTI, Spink3, TATI, TCP}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Vash2 (vasohibin 2) [NCBI Gene 226841] {aka B130052G07Rik}, TUBA1B (tubulin alpha 1b) [NCBI Gene 10376] {aka K-ALPHA-1}, PRKN (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 5071] {aka AR-JP, LPRS2, PARK2, PDJ}, SVBP (small vasohibin binding protein) [NCBI Gene 374969] {aka CCDC23, NEDAHM, SPG94}, Il5 (interleukin 5) [NCBI Gene 16191] {aka Il-5}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ZNF667 (zinc finger protein 667) [NCBI Gene 63934] {aka MIPU1}
- **Diseases:** immune-system dysregulation (OMIM:614878), DN (MESH:D003928), small-vessel vasculopathy (MESH:D059345), joint destruction (MESH:D008105), HCC (MESH:D006528), OA (MESH:D010003), bladder, (MESH:D001745), neuroendocrine tumors (MESH:D018358), proteinuria (MESH:D011507), Atopic dermatitis (MESH:D003876), Bladder Cancer (MESH:D001749), fibro (MESH:D009810), squamous cell carcinomas (MESH:D002294), Pregnancy and reproductive disorders (MESH:D011254), NSCLC (MESH:D002289), PAH (MESH:D006976), sepsis (MESH:D018805), Systemic sclerosis (MESH:D012595), Hypoxia (MESH:D000860), type-2 DN (MESH:D003924), Gastric Cancer (MESH:D013274), hypercholesterolemia (MESH:D006937), infarct (MESH:D007238), Heart Failure (MESH:D006333), autoimmune disease (MESH:D001327), TNBC (MESH:D064726), Renal diseases (MESH:D007674), Breast Cancer (MESH:D001943), obesity (MESH:D009765), diabetic microangiopathy (MESH:D003925), interstitial lung disease (MESH:D017563), AKI (MESH:D058186), Ovarian Cancer (MESH:D010051), serous carcinoma (MESH:D018297), AD (MESH:D000544), IPF (MESH:D054990), Cardiovascular Diseases (MESH:D002318), lung cancer (MESH:D008175), vasculopathy (MESH:D000090122), Immunological disorders (MESH:D007154), Cerebral ischemia (MESH:D002545), synovitis (MESH:D013585), Metabolic and vascular diseases (MESH:D014652), retinal (MESH:D012173), Diabetic (MESH:D003920), renal pathologies (MESH:D002114), Neuroendocrine Neoplasms (MESH:D009369), dcSSc (MESH:D045743), adenocarcinomas (MESH:D000230), DR (MESH:D003930), serous cystadenoma (MESH:D018293), PE (MESH:D011225), joint pain (MESH:D018771), AMD (MESH:D008268), swelling (MESH:D004487), insulin resistance (MESH:D007333), obstructive lung disease (MESH:D008173), BO (MESH:D001989), ED (MESH:D007172), ovarian, gastric, (MESH:D013276)
- **Chemicals:** oligonucleotides (MESH:D009841), serotonin (MESH:D012701), flavonoid (MESH:D005419), calcium (MESH:D002118), kaempferol (MESH:C006552), lipid (MESH:D008055), paclitaxel (MESH:D017239), cisplatin (MESH:D002945), 2',4'-BNA (-), doxorubicin (MESH:D004317)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** RPE — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_IQ82)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926144/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926144/full.md

## References

112 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926144/full.md

---
Source: https://tomesphere.com/paper/PMC12926144